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Abstract
Introduction. The aim of this study was to molecularly characterize Neisseria gonor-
rhoeae on non-cultured specimens collected from multiple anatomic sites. N. gonorrhoeae 
multiantigen sequence typing (NG-MAST) together with the gene sequence analysis of 
antimicrobial resistance (AMR) target genes were used.
Materials and methods. Seventeen genital and extra-genital samples from eight pa-
tients (7 were men who have sex with men, MSM, and 1 women who have sex with men, 
WSM) with gonorrhoea symptoms were analyzed. For 7, of the 8 patients, conventional 
culture method has been used to identify gonorrhoea. All the samples were tested with 
the rapid molecular method CEPHEID. Amplification and sequencing of porB and tbpB, 
to identify the Sequence Type (ST) by NG-MAST, and penA, mtrR, porB1b, ponA genes 
were also performed. Antimicrobial susceptibility by Etest, for the available culture posi-
tive samples, was carried out.
Results. For 7 patients the ST was obtained and for 6 the complete sequence analysis 
of the AMR target genes was also defined. For the majority of them, samples collected 
from multiple sites (oropharynx, rectum, vaginal and urethra) confirm the presence of 
the same gonorrhoea strain. In particular, for 5 patients the same STs and changes in the 
AMR target genes were identified.
Conclusion. Molecular characterization on non-cultured or culture negative specimens 
for gonorrhoea can successfully be applied directly to genital and extra-genital samples. 
Thus permit to identify the presence of the same strain in patients with gonorrhoea in-
fection in multiple anatomic sites and to predict the antimicrobial susceptibility pattern.
INTRODUCTION
Neisseria gonorrhoeae (NG) infection is nowadays con-
sidered a public health issue at international level [1].
The diagnosis of gonorrhoea consists in the cultivation 
of the pathogen, as a gold standard, and/or the identifica-
tion of DNA by nucleic acid amplification tests (NAATs) 
[2]. NAATs are approximately twice as sensitive as cul-
ture on oropharyngeal specimens [3, 4], however, it 
could generate false-positive results due to the presence 
of other Neisseria species in the oropharynx [5].
N. gonorrhoeae multiantigen sequence typing (NG-
MAST) is routinely used in gonorrhoea typing system 
for its discriminatory power and international compari-
son [6]. In addition, molecular typing permits to moni-
tor the circulation of specific NG clones, as e.g. the 
genogroup (G) 1407, an international multi-drug re-
sistant gonococcal strain with decreased susceptibility 
or resistance to cefixime, ceftriaxone and azithromycin, 
and resistance to ciprofloxacin [7, 8].
Moreover, the analysis of antimicrobial resistance 
(AMR) target genes is crucial for enhancing gonococ-
cal AMR (GONO-AMR) surveillance. Several mecha-
nisms have been extensively described to be associated 
with resistance in gonorrhoea. From them, changes 
of penA gene (encoding the penicillin-binding protein 
2-PBP2) were responsible for decreased susceptibil-
ity or resistance to extended-spectrum cephalosporin 
(ESCs) [9].
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Additionally, overexpression of the MtrCDE efflux 
pump, due to mutations in the promoter and coding 
region of the mtrR gene, together with the decreased 
membrane permeability caused by porB1b gene muta-
tions, contribute to the decreased susceptibility and re-
sistance to ESCs [9]. The role of other genes associated 
with penicillin resistance, as e.g., ponA gene (encoding 
penicillin-binding protein 1-PBP1), remains unclear.
The object of this study was to identify the same 
gonococcal strain in patients, mainly men who have 
sex with men (MSM), in multiple anatomic sites and 
to type them by NG-MAST and by gene sequencing 
of penA, mtrR, porB1b and ponA genes known to be in-




Seventeen clinical samples (genital and extra-genital), 
collected, in 2014, from eight patients with symptoms 
of gonorrhoea (urethritis and/or proctitis or cervicitis; 
no one had overtly symptomatic pharyngitis) at the 
STI Clinic, Amedeo di Savoia Hospital, Turin, Italy, re-
sulting negative or positive by culture and samples not 
cultured at all, were analyzed. For six patients, pharyn-
geal and rectal paired samples were collected; in one, 
an urethral sample was also gathered. In two patients 
pharyngeal swabs were paired with urethral and vaginal 
samples.
For three samples (gathered at pharyngeal, rectal 
and urethral sites), collected from the same patient, 
the culture was not performed at all. All the remain-
ing pharyngeal samples were culture-negative. Among 
the residual 5 rectal samples, only two were culture-
positive and the vaginal together with the remaining 
urethral samples were culture-negative and culture-
positive, respectively.
Patient clinical data were anonymously collected for 
surveillance purposes, thus no ethical approval was re-
quired.
Nucleic acid amplification test (NAAT) for CT/NG
Swabs were collected in Xpert CT/NG (Chlamydia 
trachomatis/Neisseria gonorrhoeae) Swab Transport Re-
agent tubes and processed with the Xpert CT/NG 
Assay (Cepheid, SystemsCepheid Europe SAS, Mau-
rens-Scopont France), that is an automated in vitro 
diagnostic test for the qualitative detection and dif-
ferentiation of DNA from CT and NG. The assay was 
performed on the Cepheid GeneXpert Instrument that 
integrates sample purification, nucleic acid extraction, 
amplification and detection of the target sequences us-
ing real-time PCR platform [10].
NG-MAST, penA, mtrR, porB1b, ponA analyses
A total of 17 samples resulting positive by CEPHE-
ID, were then sent to Istituto Superiore di Sanità (ISS) 
for molecular characterization.
DNA was purified using QIAamp DNA minikit (Qia-
gen, Hilden, Germany) according to the manufacturer’s 
instructions.
Genes for penA, mtrR, porB1b, ponA genes and porB 
and tbpB for the NG-MAST analysis, were amplified 
using primers and amplification parameters, as already 
described [6, 9, 11].
Thermocycling for PCR was performed using Veriti 
96 well instrument, (Applied Biosystems). Samples not 
successfully amplified in the initial reaction, were sub-
sequently re-tested in a temperature gradient amplifica-
tion program with the following cycling condition: 95 
°C for 15 min, followed by 30 cycles of 94 °C for 1 min, 
65 °C for 1 min and 72 °C for 2 min with decreasing 0.5 
°C per cycle, followed by 10 cycles of 94 °C for 1 min, 
50 °C for 1 min and 72 °C for 2 min; and a final exten-
sion step of 72 °C for 2 min.
The porB and tbpB alleles were analyzed at the NG-
MAST website (www.ng-mast.net). Closely related STs 
were clustered using published definitions as well as 
those belonging to the same genogroup [8].
Multiple sequence and amino acid alignments were 
performed using CromasPro version 1.15 and Clustal 
Omega web site (www.ebi.ac.uk/Tools/msa/clustalo/).
Antimicrobial susceptibility
A total of three strains, isolated from three patients, 
were collected from rectal (n = 2) and urethral (n = 1) 
sites. After growth on Thayer-Martin medium (Oxoid 
Ltd, Italy) with 1% IsoVitalex (Oxoid, Ltd) at 37 °C in 
a 5% CO2 atmosphere, antimicrobial susceptibility tests 
have been performed following the European Gono-
coccal Antimicrobial Surveillance Programme (EURO-
GASP) [12].
In particular, antimicrobial susceptibility to cefixime, 
ceftriaxone, ciprofloxacin and azithromycin was as-
sessed by Etest (bioMérieux, Sweden), carried out in 
agreement with the manufacturer’s instructions. World 
Health Organization (WHO) N. gonorrhoeae G, K, M, 
O, and P control strains were added in the assay [13].
RESULTS
Samples and patients
A total of 17 samples, from eight patients, were lab-
confirmed by CEPHEID. All of them were symptom-
atic with urethritis and/or proctitis or cervicitis but none 
had overtly symptomatic pharyngitis.
The patient’s nationality was as following: six Italians, 
one Rumanian and one Brazilian and the median age 
was of 26.6 years (years range 19-42). Seven were MSM 
and one was women who have sex with men (WSM). All 
the patients denied sexual contacts outside the city of 
Turin; three of them had a previous gonococcal infec-
tion and none was HIV positive. The WSM patient was 
co-infected with Trichomonas vaginalis (data not shown). 
The patients were treated with a combined therapy 
of 0.5 g of intramuscular ceftriaxone plus 1 g of oral 
azithromycin.
Molecular analyses
For all samples, except for one collected from phar-
ynx, it was possible to assign the porB and tbpB alleles 
(Table 1). The same Sequence Type (ST) was found in all 
paired samples except for one couple (ID8a, pharyngeal, 
and 8b, urethral) showing different porB and tbpB alleles 
(Table 1). In particular, as showed in Table 1, the ST292, 
























ST1352, ST5624 (belonging to G5624), ST11632 (be-
longing to G4995), ST2400 (belonging to G2400), 
ST10259, ST9909 and ST1935 have been assigned.
The penA sequences were compared with N. gonor-
rhoeae LM306 (Accession number: M32091) and N. 
gonorrhoeae NG-3 (Accession number AB071984).
As shown in Table 1, all samples showed penA non-
mosaic allele containing an aspartic acid insertion at 
position 345 (D345a). In particular, 3 paired samples, 
ID1a and 1b, 3a and 3b, 4a and 4b, and samples ID7a, 
7b and 7c showed the same nonmosaic type IV allele.
The nonmosaic type IV allele with two additional 
amino acid substitutions, A501T and P551L (Accession 
number: KP677512, [14]) was identified in ID5a and 
5b paired samples. The sample with ID8b showed penA 
nonmosaic allele V with the additional substitution 
V501T. penA allele was not determined for ID8a (Table 
1). No amplification of penA gene was obtained in two 
paired samples ID2a and 2b, 6a and 6b, respectively.
mtrR gene harbored the single adenine deletion in the 
promoter region and the T86A, H105Y, D79N amino 
acid changes in the MtrR efflux pump in ID4a and 4b, 
5a and 5b, 8a and 8b. ID4a and 4b showed the G45D 
amino acid change in the MtrR DNA-binding motif; 
ID7a, 7b, 7c showed the A39T amino acid change and 
ID3a and 3b samples harboured an insertion of adenine 
at position 17 from the ATG of the gene (Table 1). Two 
paired samples, ID2a and 2b, 6a and 6b, were negative 
for mtrR amplification reaction.
The L421P amino acid substitution in the ponA allele 
was detected in six couple of samples and in the urethra 
sample ID8b (Table 1). Moreover, samples with ID2a 
and 2b and ID6b were negatives for ponA amplification 
reaction.
The amino acid substitution A121S was found in 
PorB1b for three paired samples (ID1a and 1b, 2a and 
2b, 4a and 4b); G120D and A121G was detected in 
one couple of samples (ID3a and 3b) and G120K and 
A121D in two paired samples (ID5a and 5b, 6a and 
6b) (Table 1). ID8a and 8b showed different amino 
acid substitutions: A121D and G120K together with 
A121D, respectively.
Antimicrobial susceptibility assay results on three 
cultivated strains were in agreement with the mutation 
identify in the target genes analyzed in samples collect-
ed from the same patients. They were strains cultivated 
from the samples ID4b, 6b and 8b. The results were 
as follows: susceptible to cefixime (MIC range values 
0.016-0.023 mg/L) and ceftriaxone (MIC range values 
0.002-0.023 mg/L); resistant to ciprofloxacin (MIC 
range values 4-12 mg/L). ID4b and 6b showed a de-
creased susceptibility to azithromycin with MIC = 0.38 
mg/L and 0.25 mg/L and respectively. Moreover, ID8b 
was resistant to azithromycin with MIC = 1.5 mg/L.
Table 1 
Site of sampling, sex, sexual orientation  and age of patients and molecular characterization by NG-MAST, mtrR, penA, ponA and 








NG-MAST ST penA mtrR ponA porB1b










1a Oropharynx M MSM 21 28 4 ST292 IV D345a wt T86A; H105Y wt A121S
1b Rectum 28 4 ST292 IV D345a wt T86A; H105Y wt A121S
2a  Oropharynx F WSM 26 301 4 ST1352 NA NA NA NA NA A121S
2b Vaginal 301 4 ST1352 NA NA NA NA NA A121S
3a  Oropharynx M MSM 28 90 953 ST5624 IV D345a wt A insertion** wt G120D; A121G
3b Rectum 90 953 ST5624 IV D345a wt A insertion** wt G120D; A121G
4a  Oropharynx M MSM 21 6816 33 ST11632 IV D345a A deletion° G45D L421P A121S
4b Rectum 6816 33 ST11632 IV D345a A deletion° G45D L421P A121S
5a  Oropharynx M MSM 31 1489 563 ST2400 IV-A501T/
P551L*
D345a A deletion° D79N; T86A; 
H105Y 
L421P G120K; A121D
5b Rectum 1489 563 ST2400 IV-A501T/
P551L*
D345a A deletion° D79N; T86A; 
H105Y 
L421P G120K; A121D
6a  Oropharynx M MSM 42 1489 4 ST10259 NA NA NA NA L421P G120K; A121D
6b Rectum 1489 4 ST10259 NA NA NA NA NA G120K; A121D
7a  Oropharynx M MSM 19 5853 241 ST9909 IV D345a wt A39T wt wt
7b Rectum 5853 241 ST9909 IV D345a wt A39T wt wt
7c Urethra 5853 241 ST9909 IV D345a wt A39T wt wt
8a  Oropharynx M MSM 25 870 1005^ - NA - A deletion° D79N; T86A wt A121D
8b Urethra    182 4 ST1935 V-A501T D345a A deletion° D79N; T86A L421P G120K; A121D
* = new penA sequence pattern, accession number KP677512 [15]
** = adenine (A) insertion at nt 17 from ATG of mtrR gene
° = adenine (A) deletion in the mtrR promoter
^ = 96% of similarity with the tbpB allele 1005 
Wt = wild-type 
MSM = men who have sex with men
WSM = women who have sex with men
NA = not applicable

























Gonococcal infection is nowadays a worrisome reality 
due to the circulation of AMR and of multi-drug resis-
tant (MDR) strains [15]. In this context, it is crucial to 
define the patterns of antimicrobial susceptibility and to 
genotype those samples resulting negative by culture or 
samples not cultured at all [16]. Since the spread in the 
use of molecular techniques to identify the presence of 
gonorrhoea without a culture confirmation, it is essential 
to be able to predict at least the antimicrobial susceptibil-
ity. In order to answer to this request we analyzed 17 sam-
ples collected from several anatomic sites from 8 patients.
The analysis of penA gene showed the presence of 
nonmosaic type IV allele. It has been already described 
to be associated with ESC susceptible profile in NG [9, 
11] and recovered in Italy in cefixime susceptible NG 
[14]. Sustaining this point the T86A, H105Y, D79N, 
A39T in the MtrR efflux pump and the A121S, A121G, 
A121D, G120D, G120K amino acid changes in PorB1b 
were found [15, 17].
Moreover, STs belonging to G2400, found in the 
samples ID5a and 5b, showed penA nonmosaic allele 
IV variant with two additional amino acid substitutions 
(A501T and P551L), the substitutions D79N/T86A/
H105Y in MtrR, the L421P in PBP1 and G120K/
A121D in PorB1b, as already described [14]. For a 
MSM patient, two N. gonorrhoeae strains, one in the 
pharynx and one in the urethra, with different porB and 
tbpB alleles and two molecular profiles for antimicrobial 
resistant determinants were found. From the urethra it 
was possible to cultivate the strain confirming the resis-
tance to ciprofloxacin and the susceptibility to cefixime 
as observed by the molecular analysis on sample.
CONCLUSION
In summary, we display the molecular characteriza-
tion of gonorrhoea non-cultured or culture-negative.
In the panel of samples analyzed it was possible to 
characterize the presence of DNA associated to the 
same gonococcal strain and to predict the susceptibility 
to the antimicrobials in use for gonorrhoea therapy.
Since the large use of molecular methods for labora-
tory diagnosis of gonorrhoea the possibility to detect 
antimicrobial resistance genes provide an alternative to 
culture-based antimicrobial susceptibility testing espe-
cially in the era of global spreading of gonococci resis-
tant or multidrug resistant to antimicrobials.
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